Every Form 4 that Viking Therapeutics, Inc (VKTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VKTX filings page.
Dorothy Elizabeth Kelly-Gemmell, a director of Viking Therapeutics, Inc., received equity awards on August 1, 2026. She was granted a restricted stock unit award covering 6,333 shares of common stock, vesting in three equal annual installments, and stock options for 40,800 shares at an exercise price of $31.74 per share, also vesting one-third on each anniversary and expiring on August 1, 2036.
Viking Therapeutics, Inc. reported that President & CEO Brian Lian acquired 221,667 shares of common stock on July 28, 2026 through the vesting of a performance RSU award granted January 3, 2023. On July 29, 2026, 148,517 shares were automatically sold at a weighted-average $33.3153 per share solely to satisfy tax withholding obligations.
Viking Therapeutics, Inc. CFO Greg Zante reported two stock transactions. On July 28, 2026 he acquired 31,667 shares of common stock at no cost when 33.33% of a performance restricted stock unit award granted January 3, 2023 vested after a non‑financial goal was met. On July 29, 2026, 21,217 shares were automatically sold on a non‑discretionary basis solely to satisfy tax withholding obligations, at a weighted‑average price of $33.4704 per share in multiple trades between $33.30 and $33.805.
Viking Therapeutics, Inc. reported that Chief Operating Officer Marianna Mancini received 31,667 shares of common stock on July 28, 2026, upon vesting of a performance restricted stock unit award originally granted on January 3, 2023, after achieving a non-financial performance goal; this vesting represented 33.33% of that award. On July 29, 2026, 18,217 shares were automatically sold on a non-discretionary basis solely to satisfy tax withholding obligations related to this vesting, at a weighted average price of $33.4652 per share, within a price range of $33.28 to $33.805. Reported holdings also include 120 shares acquired on May 20, 2026 under the company’s 2024 Employee Stock Purchase Plan.
Viking Therapeutics reported that Chief Medical Officer Hubert C. Chen received a grant of stock options. The award covers 190,000 options to buy common stock at an exercise price of $31.27 per share, expiring on June 1, 2036. According to the vesting terms, 25% of the options vested immediately on the grant date, with an additional 25% vesting on each one-year anniversary over the next three years. Following this compensation-related grant, Chen holds 190,000 stock options directly.
Viking Therapeutics, Inc. reported that Chief Commercial Officer Neil William Aubuchon purchased common stock in the company. On this transaction date, he made an open-market purchase of 4,475 shares of common stock at $33.50 per share. Following this trade, he directly holds 4,475 shares of Viking Therapeutics common stock.
Viking Therapeutics Chief Commercial Officer Neil William Aubuchon received a grant of stock options on common stock. The award covers 180,000 stock options with an exercise price of $31.76 per share, expiring on 01/12/2036.
According to the vesting terms, 25% of the options vest immediately, and an additional 25% vest on each one-year anniversary of the grant date over the next three years. After this grant, Aubuchon directly holds 180,000 derivative securities in the form of these options.
Viking Therapeutics reported insider equity activity by its Chief Operating Officer. On January 2, 2026, the officer received 41,000 restricted stock units and an additional 32,049 shares from performance-based restricted stock units, both at $0 cost, increasing beneficial ownership. On the same date, the officer was also granted a stock option for 91,000 shares at an exercise price of $35.42 per share, vesting in equal annual installments over four years. On January 5, 2026, a total of 57,661 shares were automatically sold in multiple transactions at weighted-average prices between about $31.87 and $35.20 to cover tax withholding obligations tied to these vesting awards. Following these transactions, the officer beneficially owned 409,190 shares of Viking Therapeutics common stock.